ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Angiotech Completes Enrolment In Its Central Venous Catheter (CVC) Pivotal Study
Angiotech Pharmaceuticals,
Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and
medical device company, today announced the completion of enrolment in its
Central Venous Catheter (CVC) Pivotal Study, which is designed to examine
the safety and efficacy of Angiotech's 5-Fluorouracil (5-FU) coated CVC in
preventing bacterial catheter colonization when compared to another leading
anti-infective CVC.
"The 5-FU 'anti-infective' CVC is a leading example of what we
envisioned Angiotech would be able to accomplish as a fully integrated
company. This is the first product that originated from our in-house drug
screening and discovery efforts, progressed through our own internal
clinical and regulatory development process, and will be promoted and
distributed through our own marketing and sales force. In addition, since
biofilm development and implant infection is a ubiquitous problem with
medical devices, this technology could also provide the basis to develop
drug-coated versions of other commercial products within our existing
medical device portfolio," said Dr. William Hunter, President and CEO of
Angiotech.
Central venous catheters (CVC) are usually inserted into critically ill
patients for extended periods of time to administer fluids, drugs, and
nutrition, as well as facilitate frequent blood draws. One of the
complications associated with CVC implantation is infection, which can
occur when bacteria contaminate the catheter. CVC infections that progress
to bloodstream infections, or septicemia, can become life threatening.
Approximately 3.5 million CVC's are used in the U.S. annually leading
to approximately 250,000 CVC-related infections and an estimated 40,000
deaths. The cost of caring for these patients is estimated to be as high as
US $56,000 per infection. In addition, the Centers for Disease Control and
Prevention (CDC) has raised concerns about the overuse of traditional
antibiotics, which can contribute to an increase in the antibiotic
resistance of bacteria.
The principle behind using 5-FU - an approved anti-cancer drug - is
that the drug appears to effectively interrupt the colonization of an
implanted medical device by those micro-organisms that typically gain
entrance to the bloodstream via the local skin penetration of implanted
catheters. This reduction in colonization by bacteria may have a net effect
of reducing biofilm burden on the implanted catheters, making them less
likely to serve as reservoirs for additional infection. 5-FU has also been
shown to inhibit the proliferation of a number of bacterial species
directly which may be a second source of efficacy in preventing
catheter-based infections.
"An additional important benefit is that not only does the 5-FU coating
have the potential to prevent catheter-related infections as well as
traditional antiseptics and antibiotics, but since 5-FU has no clinical
application as either a systemic antibiotic or a hospital antiseptic, there
is little risk to the hospital or the community at-large of creating a
'super-bug' that is resistant to a useful class of antibiotic and can make
infection control more complex," added Dr. Hunter.
Angiotech expects to have preliminary data results compiled in the
fall, and present the final data results in early 2008 at a major
scientific symposium. Pending trial results and all necessary approvals,
Angiotech will prepare to launch the commercial product line in 2008.
About the CVC Pivotal Trial
The CVC trial is a randomized, single-blind, active-controlled,
two-arm, multi-center clinical study. The primary objective of the study is
to compare the Angiotech 5-FU coated CVC to a leading anti-infective
catheter with regards to preventing bacterial colonization. The study will
enrol at minimum 790 evaluable subjects at up to 25 investigative sites
located in the United States.
Forward Looking Statements
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the
words "believes," "may," "could", "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and constitute "forward-looking
information" within the meaning of applicable Canadian securities laws. All
such statements are made pursuant to the "safe harbor" provisions of
applicable securities legislation. Forward-looking statements may involve,
but are not limited to, comments with respect to our objectives and
priorities for 2007 and beyond, our strategies or future actions, our
targets, our estimation of potential market size, expectations for our
financial condition and the results of, or outlook for, our operations,
research development and further product and drug development. Such
forward-looking statements also involve known and unknown risks,
uncertainties and other factors that may cause the actual results, events
or developments to be materially different from any future results, events
or developments expressed or implied by such forward-looking statements.
Such factors are taken into account as part of our assumptions underlying
these forward-looking statements and include, among others, the following:
general economic and business conditions, both nationally and in the
regions in which we operate; technological changes that impact our existing
products or our ability to develop and commercialize future products;
competition; changes in business strategy or development plans; the ability
to attract and retain qualified personnel; existing governmental
regulations and changes in, or the failure to comply with, governmental
regulations; adverse results or unexpected delays in drug discovery and
clinical development processes; failure to obtain patent protection for
discoveries; loss of patent protection resulting from third party
challenges to our patents; commercialization limitations imposed by patents
owned or controlled by third parties; dependence upon, and relationships
with strategic alliance partners to develop and commercialize products and
services based on our work; our ability to obtain rights to technology from
licensors; liability for patent claims and other claims asserted against
us; the requirement for substantial funding to conduct research and
development and to expand commercialization activities or consummate
acquisitions; the size of the market and the potential market for our
products in specific disease areas, other factors referenced in our annual
information form and other filings with the applicable Canadian securities
regulatory authorities or the Securities and Exchange Commission; and any
other factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual results
expressed or implied by the forward-looking statements in this report to
differ materially from our actual results. These operating risks include:
our ability to successfully complete preclinical and clinical development
of our products; the ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products;
decisions, and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the ability to complete
and maintain corporate alliances relating to the development and
commercialization of our technology and products; market acceptance of our
technology and products; the competitive environment and impact of
technological change; the continued availability of capital to finance our
activities; our ability to integrate into our business the operations of
AMI; and, our ability to achieve the operational and other synergies and
the other commercial or financial benefits expected as a result of the
acquisition of AMI. Given these uncertainties, assumptions and risk
factors, readers are cautioned not to place undue reliance on such
forward-looking statements. We disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this report to reflect future
results, events or developments.
About Angiotech
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical
and medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases
or complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech (NASDAQ:
ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.
Angiotech Pharmaceuticals, Inc.
http://www.angiotech.com
Angiotech completeaza sale de înscriere în cateter venos central (CVC)-un studiu pivot - Angiotech Completes Enrolment In Its Central Venous Catheter (CVC) Pivotal Study - articole medicale engleza - startsanatate